Price (delayed)
$3.98
Market cap
$42.92M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.78
Enterprise value
$35.11M
Lantern Pharma (LTRN) is a clinical-stage biopharmaceutical company innovating the repurposing, revitalization and development of precision therapeutics in oncology. It leverages advances in machine learning, genomics, and artificial intelligence by
There are no recent dividends present for LTRN.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.